Wilko Weichert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/545482/publications.pdf

Version: 2024-02-01

211 papers	7,699 citations	47006 47 h-index	76900 74 g-index
216 all docs	216 docs citations	216 times ranked	13637 citing authors

#	Article	IF	Citations
1	Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. Seminars in Cancer Biology, 2022, 84, 3-15.	9.6	12
2	An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 359-368.	2.8	21
3	Aberrant <scp>DNA</scp> methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the <scp>CpG</scp> island methylator phenotype. International Journal of Cancer, 2022, 150, 617-625.	5.1	3
4	PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the â€œCancer Integrinâ€•Î±vÎ²6 with Ga-68-Trivehexin. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1136-1147.	6.4	25
5	The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner. Oncogene, 2022, 41, 1376-1382.	5.9	7
6	Elevated microsatellite instability at selected tetranucleotide (<scp>EMAST</scp>) repeats in gastric cancer: a distinct microsatellite instability type with potential clinical impact?. Journal of Pathology: Clinical Research, 2022, 8, 233-244.	3.0	3
7	Engineering a better light sheet in an axiconâ€based system using a flattened Gaussian beam of low order. Journal of Biophotonics, 2022, 15, e202100342.	2.3	7
8	Identification of treatmentâ€induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Molecular Medicine, 2022, 14, e14876.	6.9	20
9	Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer. Cancer Research, 2022, 82, PD9-07-PD9-07.	0.9	0
10	CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. British Journal of Cancer, 2022, 126, 1470-1480.	6.4	23
11	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. , 2022, 10, e004115.		9
12	MALDI Mass Spectrometry Imagingâ€”Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 2022, 14, 1763.	3.7	8
13	Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia. Cancers, 2022, 14, 1371.	3.7	3
14	Comparative Study of the Role of Interepithelial Mucosal Mast Cells in the Context of Intestinal Adenoma-Carcinoma Progression. Cancers, 2022, 14, 2248.	3.7	3
15	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2022, , .	2.5	4
16	Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung â€“ Determination and validation of optimal prognostic cut-offs. Lung Cancer, 2022, 169, 1-12.	2.0	5
17	MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree. Molecules, 2022, 27, 3464.	3.8	7
18	Abstract 4018: Long-term response to Trastuzumab in patients with advanced gastric or gastroesophageal adenocarcinoma - A retrospective study. Cancer Research, 2022, 82, 4018-4018.	0.9	0

#	Article	IF	Citations
19	Multicenter Evaluation of Tissue Classification by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Analytical Chemistry, 2022, 94, 8194-8201.	6.5	12
20	Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit.. Journal of Clinical Oncology, 2022, 40, e17571-e17571.	1.6	3
21	Unraveling most abundant mutational signatures in head and neck cancer. International Journal of Cancer, 2021, 148, 115-127.	5.1	19
22	A multicentre analytical comparison study of interâ€reader and interâ€assay agreement of four programmed deathâ€ligand 1 immunohistochemistry assays for scoring in tripleâ€negative breast cancer. Histopathology, 2021, 78, 567-577.	2.9	23
23	Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1071-1094.	4.5	21
24	Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology, 2021, 160, 346-361.e24.	1.3	48
25	Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. Cancers, 2021, 13, 808.	3.7	5
26	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Medical Genomics, 2021, 14, 62.	1.5	58
27	Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers, 2021, 13, 1048.	3.7	10
28	Single-Nucleus and In Situ RNAâ€“Sequencing Reveal Cell Topographies in the Human Pancreas. Gastroenterology, 2021, 160, 1330-1344.e11.	1.3	112
29	Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Cancers, 2021, 13, 2069.	3.7	10
30	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
31	The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Lowâ€“Expressing CancerIn VitroandIn Vivo. Cancer Immunology Research, 2021, 9, 779-789.	3.4	10
32	uPAâ€PAIâ€1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. EMBO Molecular Medicine, 2021, 13, e13110.	6.9	5
33	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors â€“ An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
34	Whole Exome Sequencing of Biliary Tubulopapillary Neoplasms Reveals Common Mutations in Chromatin Remodeling Genes. Cancers, 2021, 13, 2742.	3.7	10
35	Implementation of Mass Spectrometry Imaging in Pathology. Clinics in Laboratory Medicine, 2021, 41, 173-184.	1.4	9
36	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 70.	2.5	11

#	Article	IF	Citations
37	Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer. Cancer Discovery, 2021, 11, 3158-3177.	9.4	12
38	Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 3969.	3.7	11
39	Correlation of in vivo imaging to morphomolecular pathology in translational research: challenge accepted. EJNMMI Research, 2021, 11, 83.	2.5	3
40	Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1209-1219.	2.8	16
41	Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. , 2021, 9, e002754.		7
42	Generation of ductal organoids from normal mammary luminal cells reveals invasive potential. Journal of Pathology, 2021, 255, 451-463.	4.5	2
43	MSI testing. Der Pathologe, 2021, 42, 110-118.	1.6	9
44	The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunology, Immunotherapy, 2021, 70, 1679-1689.	4.2	18
45	Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. Journal of Experimental Medicine, 2021, 218, .	8.5	11
46	Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. Cancers, 2021, 13, 5182.	3.7	5
47	Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylinâ€“eosin-based morphologic parameters from the WHO classification. British Journal of Cancer, 2021, 125, 1632-1646.	6.4	15
48	Diverse â€˜just-rightâ€™ levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer. British Journal of Cancer, 2021, 125, 1621-1631.	6.4	9
49	Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?. Cancers, 2021, 13, 5111.	3.7	9
50	A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer. Cancers, 2021, 13, 5371.	3.7	11
51	The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging. Metabolites, 2021, 11, 752.	2.9	8
52	PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients. Breast Care, 2021, 16, 523-531.	1.4	3
53	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast, 2021, 60, 238-244.	2.2	17
54	Evaluation of Disposable Trap Column nanoLCâ€“FAIMSâ€“MS/MS for the Proteomic Analysis of FFPE Tissue. Journal of Proteome Research, 2021, 20, 5402-5411.	3.7	12

#	Article	IF	Citations
55	Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. Cancers, 2021, 13, 5941.	3.7	5
56	Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 120.	2.5	3
57	Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups. Cancers, 2021, 13, 6177.	3.7	6
58	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
59	Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes and Cancer, 2020, 59, 106-110.	2.8	4
60	Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 393-403.	2.5	26
61	Testing NTRK testing: Wetâ€lab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	2.8	52
62	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
63	Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. Breast, 2020, 49, 101-107.	2.2	13
64	Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features. Human Pathology, 2020, 102, 79-87.	2.0	8
65	Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-NaÃ¯ve Patients with Resectable Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3496.	3.7	3
66	Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation. Journal of Comparative Pathology, 2020, 181, 73-85.	0.4	3
67	3D histopathology of human tumours by fast clearing and ultramicroscopy. Scientific Reports, 2020, 10, 17619.	3.3	39
68	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	3.7	13
69	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 2020, 11, 6081-6089.	2.5	8
70	Genetically Engineered Mouse Models of Liver Tumorigenesis Reveal a Wide Histological Spectrum of Neoplastic and Non-Neoplastic Liver Lesions. Cancers, 2020, 12, 2265.	3.7	5
71	Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. International Journal of Molecular Sciences, 2020, 21, 6407.	4.1	18
72	First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer. Archives of Gynecology and Obstetrics, 2020, 302, 1461-1467.	1.7	6

#	Article	IF	Citations
73	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications, 2020, 11, 4527.	12.8	32
74	Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Journal of Clinical Medicine, 2020, 9, 1250.	2.4	13
75	Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC. British Journal of Cancer, 2020, 123, 288-297.	6.4	16
76	Significance of tumour regression in lymph node metastases of gastric and gastroâ€oesophageal junction adenocarcinomas. Journal of Pathology: Clinical Research, 2020, 6, 263-272.	3.0	16
77	New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. Anticancer Research, 2020, 40, 3109-3118.	1.1	21
78	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€˜Molecular Diagnostics and Therapyâ€™. European Journal of Cancer, 2020, 135, 1-7.	2.8	23
79	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e629-e642.	1.9	8
80	Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3616-3628.	7.0	31
81	Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2020, 9, 724.	2.4	35
82	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
83	Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers, 2020, 12, 1689.	3.7	14
84	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer, 2020, 142, 114-119.	2.0	28
85	Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. British Journal of Cancer, 2020, 122, 835-846.	6.4	11
86	Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma. European Journal of Radiology, 2020, 124, 108848.	2.6	7
87	<scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp>NTRK</scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.	2.8	27
88	Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Clinical Cancer Research, 2020, 26, 220-231.	7.0	54
89	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut, 2020, 69, 1472-1482.	12.1	61
90	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23

#	Article	IF	Citations
91	Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Journal of Clinical Investigation, 2020, 130, 4704-4709.	8.2	80
92	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
93	Lymph node infiltration, parallel metastasis and treatment success in breast cancer. Breast, 2019, 48, 1-6.	2.2	16
94	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 599-608.	2.8	45
95	Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. British Journal of Cancer, 2019, 121, 1050-1057.	6.4	11
96	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
97	A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLoS ONE, 2019, 14, e0218642.	2.5	48
98	HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFÎ²1 signalling in inflammation. Mucosal Immunology, 2019, 12, 656-667.	6.0	56
99	Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas â€“ a single center experience. Radiation Oncology, 2019, 14, 2.	2.7	14
100	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
101	Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epsteinâ€“Barr virus infection and highâ€•and lowâ€•microsatellite instability. Journal of Pathology: Clinical Research, 2019, 5, 227-239.	3.0	63
102	Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. International Journal of Cancer, 2019, 145, 3299-3310.	5.1	34
103	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nature Communications, 2019, 10, 2352.	12.8	68
104	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. OncoImmunology, 2019, 8, 1614858.	4.6	24
105	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Nodeâ€“positive study. European Journal of Cancer, 2019, 114, 76-88.	2.8	37
106	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
107	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. Pathology, 2019, 51, 362-368.	0.6	10
108	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. Histopathology, 2019, 75, 312-319.	2.9	15

#	Article	IF	Citations
109	BarrettNETâ€"a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma. Ecological Management and Restoration, 2019, 32, .	0.4	7
110	Tumor Budding and Cell Nest Size Are Highly Prognostic in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2019, 43, 303-313.	3.7	41
111	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	12.8	64
112	In MALDIâ€"Mass Spectrometry Imaging on Formalinâ€Fixed Paraffinâ€Embedded Tissue Specimen Section Thickness Significantly Influences m/z Peak Intensity. Proteomics - Clinical Applications, 2019, 13, e1800074.	1.6	19
113	Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. Strahlentherapie Und Onkologie, 2019, 195, 131-144.	2.0	4
114	Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. Journal of Clinical Pathology, 2019, 72, 285-294.	2.0	22
115	Siteâ€toâ€Site Reproducibility and Spatial Resolution in MALDIâ€"MSI of Peptides from Formalinâ€Fixed Paraffinâ€Embedded Samples. Proteomics - Clinical Applications, 2019, 13, e1800029.	1.6	73
116	Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. Gastroenterology, 2019, 156, 203-217.e20.	1.3	50
117	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
118	Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration. PLoS ONE, 2019, 14, e0208717.	2.5	8
119	Discerning the Primary Carcinoma in Malignant Peritoneal and Pleural Effusions Using Imaging Mass Spectrometryâ€"A Feasibility Study. Proteomics - Clinical Applications, 2019, 13, 1800064.	1.6	10
120	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. Journal of Immunology, 2019, 202, 278-291.	0.8	61
121	Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation. International Journal of Cancer, 2019, 144, 3160-3173.	5.1	13
122	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	2.8	75
123	Identification of MALDI Imaging Proteolytic Peptides Using LCâ€MS/MSâ€Based Biomarker Discovery Data: A Proof of Concept. Proteomics - Clinical Applications, 2019, 13, e1800158.	1.6	17
124	Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20%. Neuroendocrinology, 2019, 108, 109-120.	2.5	44
125	In vivo imaging of early stages of rheumatoid arthritis by Î±5Î²1-integrin-targeted positron emission tomography. EJNMMI Research, 2019, 9, 87.	2.5	17
126	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. European Radiology Experimental, 2019, 3, 41.	3.4	55

#	Article	IF	Citations
127	PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.. Journal of Clinical Oncology, 2019, 37, 4018-4018.	1.6	6
128	Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial.. Journal of Clinical Oncology, 2019, 37, 8543-8543.	1.6	0
129	Immunohistochemical expression of CD44 in oral squamous cell carcinoma in relation to histomorphological parameters and clinicopathological factors. Histopathology, 2018, 73, 559-572.	2.9	52
130	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1179-1187.	6.4	26
131	Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. Journal of Pathology: Clinical Research, 2018, 4, 93-102.	3.0	47
132	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancerâ€"a randomised biomarker-driven clinical phase II AIO study. European Journal of Cancer, 2018, 92, 11-19.	2.8	55
133	PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue â€“ prognostic implications and rationale for immunotherapy. OncoImmunology, 2018, 7, e1389366.	4.6	72
134	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology, 2018, 31, 829-839.	5.5	44
135	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
136	MTOR inhibitor-based combination therapies for pancreatic cancer. British Journal of Cancer, 2018, 118, 366-377.	6.4	35
137	Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Human Pathology, 2018, 77, 70-79.	2.0	95
138	Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1109-1118.	2.5	5
139	R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Annals of Surgery, 2018, 268, 1058-1068.	4.2	126
140	Proteomics in Pathology. Proteomics, 2018, 18, 1700361.	2.2	18
141	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
142	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	1.8	33
143	Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Scientific Reports, 2018, 8, 16861.	3.3	10
144	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer, 2018, 126, 80-88.	2.0	16

#	Article	IF	Citations
145	Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy. Breast Care, 2018, 13, 425-433.	1.4	8
146	NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	9.4	189
147	MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. Journal of Translational Medicine, 2018, 16, 109.	4.4	34
148	A microsatellite based multiplex PCR method for the detection of chromosomal instability in gastric cancer. Scientific Reports, 2018, 8, 12551.	3.3	8
149	Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Developmental Cell, 2018, 45, 696-711.e8.	7.0	96
150	Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget, 2018, 9, 20747-20760.	1.8	17
151	Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Oncoscience, 2018, 6, 285-286.	2.2	0
152	Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch^{Â®} system and the CellCelector^{â„¢}. Biotechnology Progress, 2017, 33, 125-132.	2.6	48
153	Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%. Modern Pathology, 2017, 30, 587-598.	5.5	162
154	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 2017, 30, 610-619.	5.5	131
155	Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology, 2017, 70, 1125-1137.	2.9	81
156	Epithelial NEMO/IKKÎ³ limits fibrosis and promotes regeneration during pancreatitis. Gut, 2017, 66, 1995-2007.	12.1	23
157	MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2017, 162, 511-521.	2.5	48
158	SMARCA4-deficient Sinonasal Carcinoma. Head and Neck Pathology, 2017, 11, 541-545.	2.6	58
159	Targeted Î±-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine, 2017, 58, 1624-1631.	5.0	367
160	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. Medical Oncology, 2017, 34, 99.	2.5	19
161	Perspective of Î±vÎ²6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Molecular Imaging, 2017, 16, 153601211770938.	1.4	24
162	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133

#	Article	IF	Citations
163	Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. British Journal of Cancer, 2017, 117, 220-226.	6.4	25
164	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 77, 3-12.	2.8	51
165	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. Medical Oncology, 2017, 34, 71.	2.5	17
166	c-Met in chromophobe renal cell carcinoma. Medical Oncology, 2017, 34, 15.	2.5	8
167	Typing of colon and lung adenocarcinoma by high throughput imaging mass spectrometry. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 858-864.	2.3	20
168	In Vivo PET Imaging of the Cancer Integrin Î±vÎ²6 Using ⁶⁸Ga-Labeled Cyclic RGD Nonapeptides. Journal of Nuclear Medicine, 2017, 58, 671-677.	5.0	49
169	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	2.8	21
170	pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. European Journal of Cancer, 2017, 84, 121-129.	2.8	57
171	Pharmacoproteomic characterisation of human colon and rectal cancer. Molecular Systems Biology, 2017, 13, 951.	7.2	44
172	EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC â€“ Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIPÂ®). Pathology Research and Practice, 2017, 213, 1530-1535.	2.3	12
173	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. European Journal of Cancer, 2017, 82, 72-79.	2.8	13
174	A new classification method for MALDI imaging mass spectrometry data acquired on formalin-fixed paraffin-embedded tissue samples. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 916-926.	2.3	32
175	MALDI imaging mass spectrometry â€” From bench to bedside. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 776-783.	2.3	54
176	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€“AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	2.8	27
177	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 962-973.	7.0	29
178	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	21.4	326
179	Mammary Analogue Secretory Carcinoma of Salivary Glands: Diagnostic Pitfall with Distinct Immunohistochemical Profile and Molecular Features. Rare Tumors, 2017, 9, 89-92.	0.6	26
180	Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer. PLoS ONE, 2017, 12, e0186847.	2.5	24

#	Article	IF	Citations
181	Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget, 2017, 8, 46756-46768.	1.8	41
182	Interlaboratory-concordance of PD-L1 IHC for NSCLC.. Journal of Clinical Oncology, 2017, 35, e20508-e20508.	1.6	0
183	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell, 2016, 30, 75-91.	16.8	144
184	Mutations in genes encoding <scp>PI3Kâ€AKT</scp> and <scp>MAPK</scp> signaling define anogenital papillary hidradenoma. Genes Chromosomes and Cancer, 2016, 55, 113-119.	2.8	29
185	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology, 2016, 29, 1165-1172.	5.5	340
186	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics, 2016, 11, 780-790.	2.7	33
187	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. Medical Oncology, 2016, 33, 120.	2.5	23
188	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a001123.	1.2	2
189	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. Molecular and Cellular Proteomics, 2016, 15, 3081-3089.	3.8	72
190	Single-Cell Analysis Uncovers Clonal Acinar Cell Heterogeneity in the Adult Pancreas. Developmental Cell, 2016, 39, 289-301.	7.0	82
191	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Journal of Physical Education and Sports Management, 2016, 2, a001180.	1.2	57
192	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes and Cancer, 2016, 55, 268-277.	2.8	28
193	Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Letters, 2016, 371, 326-333.	7.2	11
194	Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma. European Respiratory Journal, 2016, 47, 938-946.	6.7	69
195	Diagnostic PD-L1 immunohistochemistry in NSCLC: Results of the first German harmonization study.. Journal of Clinical Oncology, 2016, 34, 3028-3028.	1.6	2
196	CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget, 2016, 7, 12024-12034.	1.8	141
197	Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.. Journal of Clinical Oncology, 2016, 34, 6056-6056.	1.6	0
198	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation Oncology, 2015, 10, 146.	2.7	14

#	Article	IF	Citations
199	Surgery of gastric cancer and esophageal cancer: Does age matter?. Journal of Surgical Oncology, 2015, 112, 387-395.	1.7	36
200	Establishment of a patient-derived orthotopic osteosarcoma mouse model. Journal of Translational Medicine, 2015, 13, 136.	4.4	35
201	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. Oncologist, 2015, 20, e10-1.	3.7	10
202	Synergistic effects of crizotinib and radiotherapy in experimental EML4â€“ALK fusion positive lung cancer. Radiotherapy and Oncology, 2015, 114, 173-181.	0.6	43
203	Classical pathology and mutational load of breast cancer â€“ integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	3.0	91
204	NUT carcinoma of the thorax: Case report and review of the literature. Lung Cancer, 2015, 90, 484-491.	2.0	33
205	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. Lung Cancer, 2015, 90, 465-471.	2.0	36
206	CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate. BioMed Research International, 2014, 2014, 1-9.	1.9	13
207	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	1.8	83
208	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	1.8	58
209	Mature mediastinal teratoma with subtotal unidirectional pancreatic differentiation. Pathology Research and Practice, 2010, 206, 346-348.	2.3	7
210	Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. International Journal of Oncology, 2003, 23, 633-9.	3.3	23
211	Postâ€neoadjuvant assessment of tumour budding according to <scp>ITBCC</scp> subgroups delivers stageâ€and <scp>regressionâ€grade</scp> independent prognostic information in intestinalâ€type gastric adenocarcinoma. Journal of Pathology: Clinical Research, 0, , .	3.0	4